Upcoming event
40th Annual EAU Congress
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROonco24, UROwebinar, Webinar
Show all

Major adverse cardiovascular events following partial nephrectomy: a novel risk index

Journal of Urology, September 2021

View

The changing trends of image guided biopsy of small renal masses before intervention- an analysis of european multinational prospective eureca registry

Journal of Urology, September 2021

View

Oncologic outcomes following partial nephrectomy versus percutaneous cryoablation: a propensity score matched analysis

Journal of Urology, September 2021

View

End-stage kidney disease after partial and radical nephrectomy among patients with severe chronic kidney disease

Journal of Urology, September 2021

View

Association of tumor histology on impact of lymph node dissection on survival in t2-t3 renal cell carcinoma: analysis of the national cancer database

Journal of Urology, September 2021

View

Active surveillance in nonhereditary bilateral multifocal type i papillary renal cell carcinoma

Journal of Urology, September 2021

View

Impact of surgical approach (open vs. minimally invasive) on oncological outcomes after nephrectomy for localised renal cell carcinoma: a recur database project

Journal of Urology, September 2021

View

Surgeon-specific variation in operative outcomes for patients with clinical T1 renal masses

Journal of Urology, September 2021

View

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study

View

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

European Urology, Volume 79, Issue 4, April 2021, Pages 468-477

View

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

View

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

View
PreviousNext